Plasmon-Enhanced Digital Fluoroimmunoassay for Subfemtomolar Detection of Protein Biomarkers

Anushree Seth; Yuxiong Liu; Rohit Gupta; Zheyu Wang; Ekansh Mittal; Samhitha Kolla; Priya Rathi; Prashant Gupta; Bijal A. Parikh; Guy M. Genin; Sumanth Gandra; Gregory A. Storch; Jennifer A. Philips; Ige A. George; Srikanth Singamaneni

doi:10.1021/acs.nanolett.3c03789

Plasmon-Enhanced Digital Fluoroimmunoassay for Subfemtomolar Detection of Protein Biomarkers

Anushree Seth, Yuxiong Liu, Rohit Gupta, Zheyu Wang, Ekansh Mittal, Samhitha Kolla, Priya Rathi, Prashant Gupta, Bijal A. Parikh, Guy M. Genin, Sumanth Gandra, Gregory A. Storch, Jennifer A. Philips, Ige A. George, Srikanth Singamaneni

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Rapid and accurate quantification of low-abundance protein biomarkers in biofluids can transform the diagnosis of a range of pathologies, including infectious diseases. Here, we harness ultrabright plasmonic fluors as “digital nanolabels” and demonstrate the detection and quantification of subfemtomolar concentrations of human IL-6 and SARS-CoV-2 alpha and variant proteins in clinical nasopharyngeal swab and saliva samples from COVID-19 patients. The resulting digital plasmonic fluor-linked immunosorbent assay (digital p-FLISA) enables detection of SARS-CoV-2 nucleocapsid protein, both in solution and in live virions. Digital p-FLISA outperforms the “gold standard” enzyme-linked immunosorbent assay (ELISA), having a nearly 7000-fold lower limit-of-detection, and outperforms a commercial antigen test, having over 5000-fold improvement in analytical sensitivity. Detection and quantification of very low concentrations of target proteins holds potential for early detection of pathological conditions, treatment monitoring, and personalized medicine.

Original language	English
Pages (from-to)	229-237
Number of pages	9
Journal	Nano Letters
Volume	24
Issue number	1
DOIs	https://doi.org/10.1021/acs.nanolett.3c03789
State	Published - Jan 10 2024

Keywords

antigen test
digital immunoassay
fluorescent nanolabels
plasmon-enhanced fluorescence
protein detection

Access to Document

10.1021/acs.nanolett.3c03789

Cite this

@article{3e962691c9254906a17deccedf1e9db7,

title = "Plasmon-Enhanced Digital Fluoroimmunoassay for Subfemtomolar Detection of Protein Biomarkers",

abstract = "Rapid and accurate quantification of low-abundance protein biomarkers in biofluids can transform the diagnosis of a range of pathologies, including infectious diseases. Here, we harness ultrabright plasmonic fluors as “digital nanolabels” and demonstrate the detection and quantification of subfemtomolar concentrations of human IL-6 and SARS-CoV-2 alpha and variant proteins in clinical nasopharyngeal swab and saliva samples from COVID-19 patients. The resulting digital plasmonic fluor-linked immunosorbent assay (digital p-FLISA) enables detection of SARS-CoV-2 nucleocapsid protein, both in solution and in live virions. Digital p-FLISA outperforms the “gold standard” enzyme-linked immunosorbent assay (ELISA), having a nearly 7000-fold lower limit-of-detection, and outperforms a commercial antigen test, having over 5000-fold improvement in analytical sensitivity. Detection and quantification of very low concentrations of target proteins holds potential for early detection of pathological conditions, treatment monitoring, and personalized medicine.",

keywords = "antigen test, digital immunoassay, fluorescent nanolabels, plasmon-enhanced fluorescence, protein detection",

author = "Anushree Seth and Yuxiong Liu and Rohit Gupta and Zheyu Wang and Ekansh Mittal and Samhitha Kolla and Priya Rathi and Prashant Gupta and Parikh, {Bijal A.} and Genin, {Guy M.} and Sumanth Gandra and Storch, {Gregory A.} and Philips, {Jennifer A.} and George, {Ige A.} and Srikanth Singamaneni",

note = "Publisher Copyright: {\textcopyright} 2023 American Chemical Society.",

year = "2024",

month = jan,

day = "10",

doi = "10.1021/acs.nanolett.3c03789",

language = "English",

volume = "24",

pages = "229--237",

journal = "Nano Letters",

issn = "1530-6984",

number = "1",

}

TY - JOUR

T1 - Plasmon-Enhanced Digital Fluoroimmunoassay for Subfemtomolar Detection of Protein Biomarkers

AU - Seth, Anushree

AU - Liu, Yuxiong

AU - Gupta, Rohit

AU - Wang, Zheyu

AU - Mittal, Ekansh

AU - Kolla, Samhitha

AU - Rathi, Priya

AU - Gupta, Prashant

AU - Parikh, Bijal A.

AU - Genin, Guy M.

AU - Gandra, Sumanth

AU - Storch, Gregory A.

AU - Philips, Jennifer A.

AU - George, Ige A.

AU - Singamaneni, Srikanth

PY - 2024/1/10

Y1 - 2024/1/10

N2 - Rapid and accurate quantification of low-abundance protein biomarkers in biofluids can transform the diagnosis of a range of pathologies, including infectious diseases. Here, we harness ultrabright plasmonic fluors as “digital nanolabels” and demonstrate the detection and quantification of subfemtomolar concentrations of human IL-6 and SARS-CoV-2 alpha and variant proteins in clinical nasopharyngeal swab and saliva samples from COVID-19 patients. The resulting digital plasmonic fluor-linked immunosorbent assay (digital p-FLISA) enables detection of SARS-CoV-2 nucleocapsid protein, both in solution and in live virions. Digital p-FLISA outperforms the “gold standard” enzyme-linked immunosorbent assay (ELISA), having a nearly 7000-fold lower limit-of-detection, and outperforms a commercial antigen test, having over 5000-fold improvement in analytical sensitivity. Detection and quantification of very low concentrations of target proteins holds potential for early detection of pathological conditions, treatment monitoring, and personalized medicine.

AB - Rapid and accurate quantification of low-abundance protein biomarkers in biofluids can transform the diagnosis of a range of pathologies, including infectious diseases. Here, we harness ultrabright plasmonic fluors as “digital nanolabels” and demonstrate the detection and quantification of subfemtomolar concentrations of human IL-6 and SARS-CoV-2 alpha and variant proteins in clinical nasopharyngeal swab and saliva samples from COVID-19 patients. The resulting digital plasmonic fluor-linked immunosorbent assay (digital p-FLISA) enables detection of SARS-CoV-2 nucleocapsid protein, both in solution and in live virions. Digital p-FLISA outperforms the “gold standard” enzyme-linked immunosorbent assay (ELISA), having a nearly 7000-fold lower limit-of-detection, and outperforms a commercial antigen test, having over 5000-fold improvement in analytical sensitivity. Detection and quantification of very low concentrations of target proteins holds potential for early detection of pathological conditions, treatment monitoring, and personalized medicine.

KW - antigen test

KW - digital immunoassay

KW - fluorescent nanolabels

KW - plasmon-enhanced fluorescence

KW - protein detection

UR - http://www.scopus.com/inward/record.url?scp=85181562811&partnerID=8YFLogxK

U2 - 10.1021/acs.nanolett.3c03789

DO - 10.1021/acs.nanolett.3c03789

M3 - Article

C2 - 38146928

AN - SCOPUS:85181562811

SN - 1530-6984

VL - 24

SP - 229

EP - 237

JO - Nano Letters

JF - Nano Letters

IS - 1

ER -

Plasmon-Enhanced Digital Fluoroimmunoassay for Subfemtomolar Detection of Protein Biomarkers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this